Brokerages Set MDxHealth SA (NASDAQ:MDXH) PT at $7.75

MDxHealth SA (NASDAQ:MDXH) has earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $7.75.

A number of research firms recently issued reports on MDXH. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of MDxHealth in a research note on Tuesday, December 23rd.

MDxHealth Stock Performance

MDxHealth stock opened at $3.16 on Wednesday. The firm has a market cap of $156.42 million, a PE ratio of -4.72 and a beta of 1.61. The firm’s 50 day moving average price is $3.52 and its two-hundred day moving average price is $3.77. MDxHealth has a twelve month low of $1.36 and a twelve month high of $5.33.

MDxHealth (NASDAQ:MDXH) last issued its earnings results on Thursday, February 26th. The company reported $999.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $999.13. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The company had revenue of $29.55 million during the quarter, compared to analyst estimates of $26.05 million. Equities analysts anticipate that MDxHealth will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kennedy Capital Management LLC acquired a new stake in MDxHealth in the third quarter valued at approximately $1,826,000. FreeGulliver LLC increased its stake in shares of MDxHealth by 25.7% during the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock worth $1,135,000 after purchasing an additional 65,000 shares during the last quarter. Mink Brook Asset Management LLC raised its holdings in shares of MDxHealth by 64.9% during the 4th quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock valued at $940,000 after purchasing an additional 103,686 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of MDxHealth by 23.3% during the 4th quarter. Renaissance Technologies LLC now owns 250,100 shares of the company’s stock valued at $893,000 after purchasing an additional 47,300 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of MDxHealth by 96.0% in the 4th quarter. Russell Investments Group Ltd. now owns 194,097 shares of the company’s stock valued at $693,000 after purchasing an additional 95,054 shares during the last quarter.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.